Skip to main content
Figure 1 | BMC Medical Genomics

Figure 1

From: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Figure 1

RAS signature score relationship to Kras mutation status. RAS signature scores relative to KRAS mutation status in (A) lung cancer cell lines, (B) breast cancer cell lines, and (C) lung tumors. The Y-axis shows the RAS pathway signature score relative to the mean of all samples in the experiment. Samples in red are KRAS mutant, samples in blue are KRAS wild-type

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us